Health

Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Phoebe Sedgman, Amber Tong, and Ashleigh Furlong

June 2, 2025 at 5:22 AM UTC

Updated on

June 2, 2025 at 8:34 AM UTC

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday.